Author

Yaron Niv

DIFFERENCE BETWEEN COVID-19 ALPHA VARIANT, B.1.1.7, AND THE ORIGINAL VIRUS IN GASTROINTESTINAL SYMPTOMS AND MORTALITY, IS A NEGATIVE CORRELATION EXISTS?
DIFFERENCE BETWEEN COVID-19 ALPHA VARIANT, B.1.1.7, AND THE ORIGINAL VIRUS IN GASTROINTESTINAL SYMPTOMS AND MORTALITY, IS A NEGATIVE CORRELATION EXISTS?

Yaron Niv

DIFFERENCE BETWEEN COVID-19 ALPHA VARIANT, B.1.1.7, AND THE ORIGINAL VIRUS IN GASTROINTESTINAL SYMPTOMS AND MORTALITY, IS A NEGATIVE CORRELATION EXISTS?
DIFFERENCE BETWEEN COVID-19 ALPHA VARIANT, B.1.1.7, AND THE ORIGINAL VIRUS IN GASTROINTESTINAL SYMPTOMS AND MORTALITY, IS A NEGATIVE CORRELATION EXISTS?

RIFABUTIN TRIPLE THERAPY FOR FIRST-LINE AND RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
RIFABUTIN TRIPLE THERAPY FOR FIRST-LINE AND RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Yaron Niv  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 1,782 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 1,782 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Yaron Niv  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES
EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Yaron Niv  et al.

EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020

Yaron Niv  et al.

IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

EFFECTIVENESS OF TREATMENTS AGAINST HELICOBACTER PYLORI ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF TREATMENTS AGAINST HELICOBACTER PYLORI ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAïVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAïVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021
TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

Yaron Niv  et al.

FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)
FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)

Yaron Niv  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Yaron Niv  et al.

Item 1 - 17 / 17
1